Annual EBITDA
-$145.83 M
-$38.13 M-35.40%
December 31, 2023
Summary
- As of February 7, 2025, ADCT annual EBITDA is -$145.83 million, with the most recent change of -$38.13 million (-35.40%) on December 31, 2023.
- During the last 3 years, ADCT annual EBITDA has risen by +$93.24 million (+39.00%).
- ADCT annual EBITDA is now -59.67% below its all-time high of -$91.33 million, reached on December 31, 2017.
Performance
ADCT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$29.70 M
-$7.50 M-33.81%
September 30, 2024
Summary
- As of February 7, 2025, ADCT quarterly EBITDA is -$29.70 million, with the most recent change of -$7.50 million (-33.81%) on September 30, 2024.
- Over the past year, ADCT quarterly EBITDA has dropped by -$3.58 million (-13.73%).
- ADCT quarterly EBITDA is now -582.29% below its all-time high of -$4.35 million, reached on December 31, 2022.
Performance
ADCT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$110.43 M
+$2.00 M+1.78%
September 30, 2024
Summary
- As of February 7, 2025, ADCT TTM EBITDA is -$110.43 million, with the most recent change of +$2.00 million (+1.78%) on September 30, 2024.
- Over the past year, ADCT TTM EBITDA has increased by +$35.40 million (+24.27%).
- ADCT TTM EBITDA is now -375.61% below its all-time high of -$23.22 million, reached on June 30, 2019.
Performance
ADCT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ADCT EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -35.4% | -13.7% | +24.3% |
| 3 y3 years | +39.0% | +35.5% | +52.1% |
| 5 y5 years | -19.4% | +35.5% | +52.1% |
ADCT EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -35.4% | +36.7% | -582.3% | +46.9% | -2.5% | +52.1% |
| 5 y | 5-year | -35.4% | +39.0% | -582.3% | +76.3% | -24.7% | +54.9% |
| alltime | all time | -59.7% | +39.0% | -582.3% | +76.3% | -375.6% | +54.9% |
ADC Therapeutics SA EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$29.70 M(+33.8%) | -$110.43 M(-1.8%) |
| Jun 2024 | - | -$22.20 M(-31.5%) | -$112.43 M(-14.7%) |
| Mar 2024 | - | -$32.42 M(+24.1%) | -$131.76 M(-9.6%) |
| Dec 2023 | -$145.83 M(+35.4%) | -$26.11 M(-17.6%) | -$145.83 M(+17.5%) |
| Sep 2023 | - | -$31.70 M(-23.7%) | -$124.06 M(-5.8%) |
| Jun 2023 | - | -$41.53 M(-10.6%) | -$131.75 M(-9.9%) |
| Mar 2023 | - | -$46.48 M(+967.7%) | -$146.16 M(+35.7%) |
| Dec 2022 | -$107.70 M(-53.3%) | -$4.35 M(-88.9%) | -$107.70 M(-27.9%) |
| Sep 2022 | - | -$39.39 M(-29.6%) | -$149.42 M(-15.3%) |
| Jun 2022 | - | -$55.93 M(+597.4%) | -$176.51 M(-7.0%) |
| Mar 2022 | - | -$8.02 M(-82.6%) | -$189.71 M(-17.7%) |
| Dec 2021 | -$230.53 M | -$46.07 M(-30.7%) | -$230.53 M(-3.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$66.48 M(-3.8%) | -$237.62 M(+25.7%) |
| Jun 2021 | - | -$69.14 M(+41.6%) | -$189.04 M(-22.8%) |
| Mar 2021 | - | -$48.84 M(-8.1%) | -$245.02 M(+2.5%) |
| Dec 2020 | -$239.06 M(+109.5%) | -$53.15 M(+196.9%) | -$239.06 M(+8.4%) |
| Sep 2020 | - | -$17.90 M(-85.7%) | -$220.53 M(-5.5%) |
| Jun 2020 | - | -$125.12 M(+191.7%) | -$233.32 M(+77.5%) |
| Mar 2020 | - | -$42.89 M(+23.9%) | -$131.42 M(+48.4%) |
| Dec 2019 | -$114.10 M(-6.6%) | - | - |
| Dec 2019 | - | -$34.62 M(+12.8%) | -$88.53 M(+64.2%) |
| Sep 2019 | - | -$30.69 M(+32.2%) | -$53.91 M(+132.2%) |
| Jun 2019 | - | -$23.22 M | -$23.22 M |
| Dec 2018 | -$122.13 M(+33.7%) | - | - |
| Dec 2017 | -$91.33 M | - | - |
FAQ
- What is ADC Therapeutics SA annual EBITDA?
- What is the all time high annual EBITDA for ADC Therapeutics SA?
- What is ADC Therapeutics SA annual EBITDA year-on-year change?
- What is ADC Therapeutics SA quarterly EBITDA?
- What is the all time high quarterly EBITDA for ADC Therapeutics SA?
- What is ADC Therapeutics SA quarterly EBITDA year-on-year change?
- What is ADC Therapeutics SA TTM EBITDA?
- What is the all time high TTM EBITDA for ADC Therapeutics SA?
- What is ADC Therapeutics SA TTM EBITDA year-on-year change?
What is ADC Therapeutics SA annual EBITDA?
The current annual EBITDA of ADCT is -$145.83 M
What is the all time high annual EBITDA for ADC Therapeutics SA?
ADC Therapeutics SA all-time high annual EBITDA is -$91.33 M
What is ADC Therapeutics SA annual EBITDA year-on-year change?
Over the past year, ADCT annual EBITDA has changed by -$38.13 M (-35.40%)
What is ADC Therapeutics SA quarterly EBITDA?
The current quarterly EBITDA of ADCT is -$29.70 M
What is the all time high quarterly EBITDA for ADC Therapeutics SA?
ADC Therapeutics SA all-time high quarterly EBITDA is -$4.35 M
What is ADC Therapeutics SA quarterly EBITDA year-on-year change?
Over the past year, ADCT quarterly EBITDA has changed by -$3.58 M (-13.73%)
What is ADC Therapeutics SA TTM EBITDA?
The current TTM EBITDA of ADCT is -$110.43 M
What is the all time high TTM EBITDA for ADC Therapeutics SA?
ADC Therapeutics SA all-time high TTM EBITDA is -$23.22 M
What is ADC Therapeutics SA TTM EBITDA year-on-year change?
Over the past year, ADCT TTM EBITDA has changed by +$35.40 M (+24.27%)